Diana Brainard - 17 May 2021 Form 4 Insider Report for Allovir, Inc. (ALVR)

Role
Chief Executive Officer, Director
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Issuer symbol
ALVR
Transactions as of
17 May 2021
Net transactions value
$0
Form type
4
Filing time
18 May 2021, 17:08:55 UTC
Next filing
15 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Award $0 +30,000 +476% $0.000000 36,300 17 May 2021 Direct F1
transaction ALVR Common Stock Award $0 +170,000 +468% $0.000000 206,300 17 May 2021 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALVR Stock Option (Right to Buy) Award $0 +500,000 $0.000000 500,000 17 May 2021 Common Stock 500,000 $23.74 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 17, 2022.
F2 The shares reported in this transaction represent RSUs issued under the Plan. 25% of these RSUs shall vest on May 17, 2022, with the remainder vesting in twelve quarterly installmenters thereafter.
F3 25% of this option shall vest and become exercisable on May 17, 2022, with the remainder vesting in twelve quarterly installments thereafter.